ATR vs HAE

Key Takeaways

• ATR (AptarGroup) is a diversified drug delivery and consumer product dispensing leader with a $8.5 billion market cap, 32 consecutive years of dividend increases, and full-year 2025 revenue of $3.78 billion.
• HAE (Haemonetics) is a medical technology company focused on plasma collection, blood management, and hospital solutions, currently trading with a market cap of approximately $3.64 billion after completing a multi-year portfolio transformation.
• AptarGroup offers a lower P/E ratio (~22) and a consistent ~1.45% dividend yield, while Haemonetics carries a higher P/E (~39) with no dividend but stronger recent price momentum.
• Haemonetics has surged roughly 31% over the trailing three months, while AptarGroup has posted a more modest ~7% gain over the same period, reflecting different market narratives driving each stock.
• Both companies have experienced year-over-year earnings pressure from segment-specific headwinds, yet each maintains a consensus "Buy" rating from Wall Street analysts.
• Risk profiles diverge meaningfully: AptarGroup's beta of 0.38 signals defensive stability, whereas Haemonetics' beta of 0.52 and ongoing portfolio transition introduce greater variability.

Introduction

Investors evaluating mid-to-large-cap equities in the healthcare-adjacent industrial and medical technology sectors frequently encounter two distinct names: AptarGroup and Haemonetics. Though each touches the broader healthcare ecosystem, their business models, growth trajectories, and risk profiles could hardly be more different. ATR is a global dispensing and drug delivery packaging powerhouse with decades of steady capital returns. HAE is a specialized medical device company navigating the tail end of a strategic transformation. This comparison examines how these two stocks stack up across performance, fundamentals, and market positioning, helping traders and longer-term investors assess which name may better suit their objectives in the current environment.

ATR Overview and Recent Performance

AptarGroup, Inc. (ATR) operates across three segments — Pharma, Beauty, and Closures — designing and manufacturing dispensing pumps, aerosol valves, and elastomeric components used in prescription drugs, injectables, fragrance, personal care, and food and beverage applications. The company reported full-year 2025 revenue of $3.78 billion, a 5% increase year-over-year, while net income rose 5% to $393 million. Reported earnings per share (EPS) reached $5.89, up 7% from the prior year. In the fourth quarter of 2025, reported sales jumped 14% to $963 million, fueled by double-digit growth in Beauty and steady gains in Pharma injectables, including GLP-1 (glucagon-like peptide-1) elastomeric components. However, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin compressed to approximately 19.8% from 23.0% a year earlier, reflecting product mix shifts, higher production costs, and a decline in emergency medicine sales. AptarGroup's Board subsequently authorized a new $600 million share repurchase program, reinforcing its commitment to shareholder returns alongside a $0.48 quarterly dividend, marking the 32nd consecutive year of annual dividend increases. As of late July 2026, shares traded near $133, with a year-to-date gain of roughly 9% and a 52-week range spanning from approximately $103 to $164.

HAE Overview and Recent Performance

Haemonetics Corporation (HAE) is a Boston-based medical technology firm specializing in blood and plasma collection systems, hospital hemostasis management, and vascular closure devices. The company operates through Plasma, Blood Center, and Hospital segments. Haemonetics recently completed a four-year strategic transformation program aimed at pivoting its portfolio toward higher-growth, higher-margin product lines, including the divestiture of its Whole Blood business and the planned ramp-down of a legacy plasma supply agreement with CSL. In its most recent fiscal year, revenue totaled approximately $1.33 billion, representing a roughly 2% decline, while net income contracted sharply to about $97 million. Despite top-line pressure, Haemonetics has delivered notable margin expansion, with adjusted operating margins reaching the mid-20% range. The Hospital segment — particularly Blood Management Technologies such as the TEG 6s viscoelastic testing platform — has been a bright spot, while the Plasma segment's organic growth, excluding CSL-related headwinds, surged nearly 30% in recent quarters. Recent catalysts include FDA (Food and Drug Administration) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology and expanded labeling for the VASCADE MVP XL vascular closure device. As of late July 2026, shares traded near $80, reflecting a three-month surge of roughly 31%, though the stock remained virtually flat year-to-date, with a 52-week range between approximately $47 and $87.

Trending AI Robots

For traders seeking data-driven assistance in navigating comparisons like this one, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of different tickers across diverse strategies, timeframes, and risk profiles. Only the most effective and market-aligned bots earn a place in the Trending AI Robots section — a dynamic showcase where traders can explore real-time performance metrics. Depending on the bot, users may encounter annualized returns ranging from moderate single digits to well over 100%, win rates from approximately 55% to above 85%, and profit factors exceeding 2.0 or even 4.0 in select cases. These bots employ distinct trading styles — from swing trading and trend-following to intraday price action — across holding periods that range from minutes to weeks. Whether you lean toward the defensive consistency of an ATR or the turnaround momentum of an HAE, visiting the Trending AI Robots page can help you discover AI-driven strategies tailored to current market conditions.

Head-to-Head Comparison

At the business model level, AptarGroup and Haemonetics serve fundamentally different roles. AptarGroup is an industrial-packaging and drug-delivery supplier whose diversified revenue streams span pharmaceuticals, beauty, and consumer goods, making it a relatively defensive compounder with global scale. Haemonetics, by contrast, is a focused medical device company concentrated in plasma collection and hospital-based blood management technologies, giving it higher exposure to procedure volumes, regulatory approvals, and competitive dynamics in niche healthcare markets.

On valuation, the contrast is stark. AptarGroup trades at a forward P/E (price-to-earnings) in the low-20s with a dividend yield near 1.45%, reflecting a mature, cash-generative profile. Haemonetics carries a trailing P/E near 39 — elevated due to recent earnings compression — but a forward P/E closer to 15, suggesting markets expect a significant earnings recovery as transformation-related headwinds recede.

Momentum tells a different story. Haemonetics has enjoyed a powerful rally over recent months, gaining roughly 31% in the trailing three-month period, fueled by better-than-expected quarterly results, FDA clearances, and growing analyst confidence in the post-transformation earnings trajectory. AptarGroup's three-month gain of roughly 7% reflects steadier, less volatile appreciation, consistent with its low-beta profile (0.38 versus HAE's 0.52).

Risk factors diverge as well. AptarGroup faces headwinds from emergency medicine destocking, product mix pressure on margins, and exposure to European currency fluctuations. Haemonetics must contend with the lingering revenue drag from the CSL contract wind-down, competitive pressures in vascular closure, and execution risk tied to new product commercialization. For income-oriented investors, AptarGroup's 32-year dividend growth streak is a meaningful differentiator, as Haemonetics does not currently pay a dividend.

Tickeron AI Verdict

Based on observable trend consistency, stability metrics, and relative positioning, Tickeron's AI-driven analytical framework would likely tilt favorably toward ATR in a risk-adjusted, longer-horizon assessment. AptarGroup's lower beta, diversified revenue base, consistent profitability, and multi-decade track record of returning capital to shareholders align well with AI models that prioritize trend durability and lower drawdown potential. That said, HAE could receive a stronger signal from momentum-oriented or catalyst-driven AI strategies, given its recent price surge, improving margin profile, and tangible product-related catalysts such as new FDA clearances and international product rollouts. In a probabilistic framework, AptarGroup appears the steadier compounder, while Haemonetics presents a higher-beta turnaround proposition that may appeal to algorithms calibrated for growth acceleration and mean-reversion setups. Neither stock is without near-term challenges, but the AI's preference would ultimately depend on whether the model is optimizing for stability or for momentum capture in the current market regime.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations